Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortization of Deferred ChargesAmortizatization of IntangiblesAmortizatization of IntangiblesAsset Writedowns and ImpairmentAsset Writedowns and ImpairmentCapital ExpendituresCapital ExpendituresCash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in Account PayablesChange in Account PayablesChange in Accured ExpensesChange in Accured ExpensesChange in CashChange in InventoryChange in InventoryChange in ReceivablesChange in ReceivablesChange in TaxesChange in TaxesDepreciation & Amortization (CF)Depreciation & Amortization (CF)Depreciation and DepletionDepreciation and DepletionExchange Rate EffectExchange Rate EffectFree Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesNet Cash FlowNet Cash FlowNet IncomeOther Working Capital ChangesOther Working Capital ChangesShare-based CompensationShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

ADC Therapeutics (ADCT) Net Cash Flow (2019 - 2026)

ADC Therapeutics has reported Net Cash Flow over the past 8 years, most recently at -$30.3 million for Q1 2026.

  • Quarterly results put Net Cash Flow at -$30.3 million for Q1 2026, up 46.16% from a year ago — trailing twelve months through Mar 2026 was $36.2 million (up 191.09% YoY), and the annual figure for FY2025 was $10.2 million, up 136.77%.
  • Net Cash Flow reached -$30.3 million in Q1 2026 per ADCT's latest filing, down from $26.6 million in the prior quarter.
  • Across five years, Net Cash Flow topped out at $69.7 million in Q2 2025 and bottomed at -$139.8 million in Q4 2022.
  • Median Net Cash Flow over the past 5 years was -$23.1 million (2024), compared with a mean of -$13.9 million.
  • Peak annual rise in Net Cash Flow hit 68499.1% in 2023, while the deepest fall reached 859017.79% in 2023.
  • Over 5 years, Net Cash Flow stood at -$139.8 million in 2022, then skyrocketed by 77.14% to -$32.0 million in 2023, then rose by 27.84% to -$23.1 million in 2024, then skyrocketed by 215.45% to $26.6 million in 2025, then plummeted by 213.9% to -$30.3 million in 2026.
  • Business Quant data shows Net Cash Flow for ADCT at -$30.3 million in Q1 2026, $26.6 million in Q4 2025, and -$29.8 million in Q3 2025.